Author Archives: Taylor Mercado

PMID:  Pediatr Infect Dis J. 2012 Sep ;31(9):977-9. PMID: 22572750 Abstract Title:  Neonatal vaccine-strain varicella-zoster virus infection 22 days after maternal postpartum vaccination. Abstract:  A 25-day-old infant developed varicella 22 days after her mother received varicella vaccine postpartum. Infection with vaccine-strain varicella-zoster virus was confirmed by genetic analysis. The mother had no postvaccination rash nor …

Continue reading “The varicella vaccine strain can cross the placenta and infect the fetus.”

PMID:  J Intern Med. 2012 May ;271(5):510-20. Epub 2011 Nov 22. PMID: 22026504 Abstract Title:  Safety of zoster vaccine in adults from a large managed-care cohort: a Vaccine Safety Datalink study. Abstract:  OBJECTIVES: The aim of this study was to examine a large cohort of adults who received the zoster vaccine for evidence of an …

Continue reading “The risk of allergic reaction was signficantly increased within 1-7 days of herpes zoster vaccination.”

PMID:  J Infect Dis. 2012 May 1 ;205(9):1331-3. Epub 2012 Mar 27. PMID: 22454471 Abstract Title:  Varicella zoster virus transmission in the vaccine era: unmasking the role of herpes zoster. Abstract:  [n/a] read more

PMID:  BMC Infect Dis. 2012 Apr 30 ;12:105. Epub 2012 Apr 30. PMID: 22545865 Abstract Title:  Recurrent 6th nerve palsy in a child following different live attenuated vaccines: case report. Abstract:  BACKGROUND: Recurrent benign 6th nerve palsy in the paediatric age group is uncommon, but has been described following viral and bacterial infections. It has …

Continue reading “A case report of recurrent benign 6th nerve palsy following measles-mumps-rubella and varicella vaccines, given on separate occasions.”

PMID:  Pediatr Allergy Immunol. 2012 Feb ;23(1):50-8. Epub 2011 Oct 21. PMID: 22017482 Abstract Title:  Chickenpox in childhood is associated with decreased atopic disorders, IgE, allergic sensitization, and leukocyte subsets. Abstract:  BACKGROUND: Wild-type varicella zoster infection (WTVZV) up to 8 yr of age has been shown to protect against atopic dermatitis (AD) and asthma. We …

Continue reading “Childhood chickenpox is associated with decreased atopic disorders, IgE allergic sensitization, and leukocyte subsets.”

PMID:  Pediatrics. 2011 Sep ;128(3):630-2. Epub 2011 Aug 28. PMID: 21873692 Abstract Title:  Policy statement—Prevention of varicella: update of recommendations for use of quadrivalent and monovalent varicella vaccines in children. Abstract:  Two varicella-containing vaccines are licensed for use in the United States: monovalent varicella vaccine (Varivax [Merck&Co, Inc, West Point, PA]) and quadrivalent measles-mumps-rubella-varicella vaccine …

Continue reading “A personal or family (such as a sibling or parent) history of seizures is now a precaution for MMRV vaccination.”

PMID:  Pediatrics. 2010 Jul ;126(1):e1-8. Epub 2010 Jun 29. PMID: 20587679 Abstract Title:  Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures. Abstract:  OBJECTIVE: In February 2008, we alerted the Advisory Committee on Immunization Practices to preliminary evidence of a twofold increased risk of febrile seizures after the combination measles-mumps-rubella-varicella (MMRV) vaccine when compared with …

Continue reading “Among 12- to 23-month-olds who received their first dose of measles-containing vaccine, fever and seizure were elevated 7 to 10 days after vaccination. Vaccination with MMRV results in 1 additional febrile seizure for every 2300 doses.”

PMID:  MMWR Recomm Rep. 2010 May 7 ;59(RR-3):1-12. PMID: 20448530 Abstract Title:  Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). Abstract:  This report presents new recommendations adopted in June 2009 by CDC's Advisory Committee on Immunization Practices (ACIP) regarding use of the combination measles, mumps, …

Continue reading “Not only can the vaccine strain itself cause varicella, but vaccine failure is common and may lead to wild-type infection.”

PMID:  Pharmacol Res. 2020 Jan 3 ;152:104630. Epub 2020 Jan 3. PMID: 31911245 Abstract Title:  Ginsenoside Rg1 and the control of inflammation implications for the therapy of type 2 diabetes: A review of scientific findings and call for further research. Abstract:  The incidence of type 2 diabetes (T2D) is gradually assuming pandemic proportions, leaving in …

Continue reading “Ginsenoside Rg1 and the control of inflammation implications for the therapy of type 2 diabetes.”

PMID:  FASEB J. 2020 Jan ;34(1):208-221. Epub 2019 Nov 20. PMID: 31914640 Abstract Title:  Ginsenoside Rg3 suppresses the NLRP3 inflammasome activation through inhibition of its assembly. Abstract:  Ginsenoside Rg3 is one of the main constituents of Panax ginseng. Compelling evidence has demonstrated that ginsenoside Rg3 is capable of inhibiting inflammation. However, the mechanism mediating its …

Continue reading “Ginsenoside Rg3 suppresses the NLRP3 inflammasome activation through inhibition of its assembly.”